A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab

This is a Phase I, multicentre study that will consist of 2 parts - * Part 1: Dose Escalation * Part 2: Dose Expansion Part 1 may include participants with solid tumours - non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC) or limited-stage small cell lung cancer (LS-SCLC). It will further consist of 2 planned dose levels of SC durvalumab - Dose level 1 (DL1) and Dose level 2 (DL2). Part 2 will include participants with unresectable HCC. It will be initiated once a dose has been identified based on Part 1.